RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|5|1480-1496

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.5, 2015-11, pp. : 1480-1496

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Downregulation of ARNT2 promotes tumor growth and predicts poor prognosis in human hepatocellular carcinoma

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 1085-1093

John Wiley & Sons Inc

Access to resources Recommend Favorite

Loss of CD155 expression predicts poor prognosis in hepatocellular carcinoma

By  

HISTOPATHOLOGY, Vol. 66, Iss. 5, 2015-04 ,pp. : 706-714

John Wiley & Sons Inc

Access to resources Recommend Favorite

BARX2 in hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 2, 2015-01 ,pp. : 228-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of Active Fraction of Glycogen Synthase Kinase 3β in Cancer Cells by Nonradioisotopic in vitro Kinase Assay

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 297-305

Karger

Access to resources Recommend Favorite

Region‐specific dysregulation of glycogen synthase kinase‐3β and β‐catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia

By  

BIPOLAR DISORDERS (ELECTRONIC), Vol. 17, Iss. 2, 2015-03 ,pp. : 160-171

John Wiley & Sons Inc

Access to resources Recommend Favorite